GLP-1 for Knee Osteoarthritis: Pain Relief, Weight Loss, PRP, Stem Cells or Surgery?

October 22, 2026

Updated October 22, 2026 | By the OneDayMD Research Team

Can GLP-1 medications such as semaglutide help people with knee osteoarthritis avoid injections or knee replacement? The answer is more encouraging than it was a few years ago, but important uncertainties remain.

A major randomized trial published in the New England Journal of Medicine found that semaglutide improved both body weight and knee osteoarthritis symptoms in people with obesity. In September 2026, the American College of Rheumatology (ACR) added a conditional recommendation for GLP-1 receptor agonists to help people with knee osteoarthritis and obesity achieve an appropriate weight, alongside diet and exercise.

However, losing weight, relieving pain, regenerating damaged cartilage and avoiding surgery are different outcomes. Evidence supporting one does not automatically prove the others.

This guide compares GLP-1 medications with platelet-rich plasma (PRP), stem-cell injections, conventional osteoarthritis care and knee replacement. It is intended for patients, caregivers and healthcare professionals seeking an evidence-based overview.

Key Takeaways

GLP-1 medications: Semaglutide has randomized-trial evidence showing improved knee pain, physical function and weight in people with obesity and moderate-to-severe symptomatic knee osteoarthritis.
Weight loss: Reducing excess body weight can improve symptoms and physical function. Exercise and resistance training remain important even when medication is used.
Direct pain relief: The extent to which GLP-1 medications relieve joint pain independently of weight loss is not yet established.
PRP: Some trials report symptom improvements, but results are inconsistent. The 2026 ACR guidance strongly recommends against routine PRP treatment for knee and hip osteoarthritis.
Stem-cell injections: There is insufficient evidence to recommend them as routine knee osteoarthritis treatment, and claims of cartilage regeneration or avoiding replacement are not established.
Knee replacement: It remains an important treatment for advanced osteoarthritis when pain and disability substantially affect quality of life despite appropriate nonsurgical treatment.

1. What Did the Semaglutide STEP 9 Trial Show?

The most important randomized clinical trial directly addressing this question is STEP 9, published in the New England Journal of Medicine in October 2024.

The trial enrolled 407 adults with obesity and moderate knee osteoarthritis accompanied by at least moderate pain. Participants received once-weekly injectable semaglutide 2.4 mg or placebo for 68 weeks. Both groups also received counseling on physical activity and a reduced-calorie diet.

Main results at week 68:

Outcome	Semaglutide	Placebo
Mean body-weight change	−13.7%	−3.2%
Change in WOMAC pain score	−41.7 points	−27.5 points
Improvement in SF-36 physical-function score	+12.0 points	+6.5 points

Interpretation: The WOMAC pain scale was normalized to 0–100, with higher scores indicating worse pain. The reported changes are improvements from baseline, not the percentage of patients who became pain-free.

Semaglutide produced significantly greater improvements than placebo in weight, knee pain and physical function. The placebo group also improved, which reinforces the importance of diet, physical activity, study participation and other factors in symptom management.

These results are clinically relevant, but the study does not establish that semaglutide repairs damaged cartilage or that every patient will experience the same degree of relief.

Evidence assessment: High-quality randomized evidence for improved weight and symptoms in a specific population of adults with obesity and symptomatic knee osteoarthritis.

Primary source: Bliddal H, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine. 2024;391:1573–1583. Read the original trial.

2. Is GLP-1 Relieving Knee Pain Directly, or Mainly Through Weight Loss?

This is one of the most important unanswered questions in the emerging GLP-1 and osteoarthritis research.

How weight loss may help

Excess body weight can increase the mechanical load placed on the knee during standing, walking and other weight-bearing activities. Obesity is also associated with metabolic and inflammatory changes that may contribute to osteoarthritis symptoms.

Weight loss may therefore help through several overlapping pathways:

Reduced mechanical loading: Less body weight can reduce the forces experienced by the knee during movement.
Improved mobility: Reduced pain and better exercise tolerance may make it easier to strengthen the muscles supporting the joint.
Metabolic changes: Improvements in metabolic health and inflammatory signaling may contribute to overall musculoskeletal health, although the clinical importance of particular pathways remains uncertain.

Why the trial does not prove a direct analgesic effect

STEP 9 randomized patients to semaglutide or placebo, not to groups with identical weight loss. Participants receiving semaglutide lost substantially more weight. As a result, the trial cannot isolate how much of the additional pain improvement came from weight reduction versus other medication-related effects.

There is also an important contrasting study involving liraglutide.

In a 2021 randomized trial, 156 participants with knee osteoarthritis and overweight or obesity were assigned to liraglutide or placebo after an initial diet-induced weight-loss period. During the subsequent 52 weeks, liraglutide helped maintain a more favorable weight trajectory, but did not produce a statistically significant additional improvement in knee pain compared with placebo.

The two trials differed in their design, treatment, participants and weight-loss trajectories. They should not be treated as directly interchangeable. Nevertheless, the liraglutide result is a useful reminder that greater weight reduction does not guarantee additional pain relief in every setting.

Laboratory research has suggested possible anti-inflammatory and cartilage-related effects of GLP-1 signaling. These mechanisms are biologically interesting, but laboratory findings do not establish cartilage regeneration or disease modification in humans.

What we can conclude: Semaglutide can improve knee osteoarthritis symptoms in people with obesity. Whether it has clinically meaningful pain-relieving or cartilage-protective effects independent of weight loss remains uncertain.

Sources: 2021 liraglutide randomized trial and the 2024 STEP 9 trial.

3. What Does the 2026 ACR Guidance Mean for Patients?

On September 14, 2026, the American College of Rheumatology published its updated osteoarthritis guidance, replacing the 2019 recommendations.

The new guidance conditionally recommends GLP-1 receptor agonists for people who have both knee osteoarthritis and obesity, specifically to help achieve an appropriate weight in combination with diet and exercise. The certainty of evidence for this recommendation is rated moderate.

For context, the guidance strongly recommends exercise and weight loss for people with knee or hip osteoarthritis who meet criteria for overweight or obesity.

A conditional recommendation is not the same as a universal prescription. It means that a treatment can be reasonable for selected patients after weighing potential benefits, adverse effects, cost, access and individual circumstances.

Crucially, the GLP-1 recommendation concerns weight management. It does not establish GLP-1 medicines as a proven cartilage-regenerating therapy or as a replacement for orthopedic assessment.

Source: American College of Rheumatology — 2026 Osteoarthritis Guideline.

4. GLP-1 vs PRP vs Stem Cells vs Knee Replacement

These treatments address different problems. GLP-1 medication can help eligible patients manage obesity; PRP and stem-cell injections are intended as local joint treatments; and knee replacement addresses the mechanical consequences of advanced joint damage.

GLP-1 medication

Primary target: Excess body weight and related metabolic health.

Potential knee benefit: Improved pain and function, supported by the semaglutide STEP 9 trial in patients with obesity and symptomatic knee osteoarthritis.

Main limitation: Direct joint effects and prevention of cartilage loss have not been established. Treatment requires attention to adverse effects, affordability and long-term weight management.

Platelet-rich plasma (PRP)

Primary target: Local joint symptoms using a preparation made from the patient's own blood.

Potential knee benefit: Some studies report improvements in pain and function, but results vary with study design, PRP preparation and comparator.

Main limitation: Evidence remains inconsistent. The 2026 ACR guidance strongly recommends against PRP for routine knee and hip osteoarthritis treatment.

Stem-cell injections

Primary target: Marketed as a regenerative or biologic approach to joint disease.

Potential knee benefit: Experimental approaches are being investigated, but reliable clinical evidence of meaningful cartilage regeneration or consistent superiority over established care is lacking.

Main limitation: Products and procedures vary considerably. The 2026 ACR guidance strongly recommends against stem-cell injections for routine knee and hip osteoarthritis treatment.

Knee replacement surgery

Primary target: Advanced joint damage that causes substantial pain, loss of mobility or reduced quality of life.

Potential knee benefit: Can substantially improve pain and function in appropriately selected patients with advanced osteoarthritis.

Main limitation: It is a major operation with recovery demands, potential complications and the possibility of persistent symptoms. It is not usually the first step for early disease.

Bottom line: GLP-1 medication and knee replacement should not be viewed as mutually exclusive choices. A patient may benefit from weight management and rehabilitation while also being assessed for surgery. PRP and stem-cell injections should not be assumed to regenerate cartilage simply because they are marketed as regenerative treatments.

5. Is PRP Worth Paying For?

PRP is made by processing a sample of a patient's blood to concentrate platelets and related biological components. It is then injected into the joint.

Platelets contain growth factors and signaling molecules that have prompted interest in tissue repair. However, the biological rationale does not by itself demonstrate that a treatment restores cartilage or changes the natural course of osteoarthritis.

Why PRP research is difficult to interpret

PRP is not a single standardized product. Studies can differ in platelet concentration, leukocyte content, preparation methods, number of injections, osteoarthritis severity and the comparison treatment used.

Some trials and meta-analyses report better pain or function scores after PRP, including comparisons with hyaluronic acid. Other analyses find limited or inconsistent improvements, particularly when PRP is compared with a placebo injection.

The 2021 American Academy of Orthopaedic Surgeons guideline described the evidence for PRP as limited. The updated 2026 ACR guidance takes a stronger position and recommends against PRP for routine knee and hip osteoarthritis treatment, rating the certainty of evidence as low.

The distinction matters: an uncertain treatment may help some individuals, but that possibility does not justify claims that it is reliably effective or that it rebuilds cartilage.

Questions to ask before considering PRP

What is the proposed treatment goal: pain relief, improved function or structural repair?
What evidence supports the specific preparation and injection protocol being offered?
What are the realistic chances of improvement, duration of benefit and potential complications?
What is the total cost, including repeat injections, and what established alternatives are available?

PRP is often paid for privately. Patients should be cautious about paying substantial sums based on guaranteed-success claims, testimonials or promises to avoid knee replacement.

Sources: AAOS knee osteoarthritis clinical practice guideline and the 2026 ACR osteoarthritis guidance.

6. Do Stem-Cell Injections Regenerate Knee Cartilage?

Stem-cell and other cell-based interventions are often promoted as a way to repair cartilage, reduce inflammation or avoid joint replacement. Some clinics use terms such as regenerative medicine, biological reconstruction or cellular therapy.

These terms can create the impression that an established regenerative treatment is available. For routine knee osteoarthritis, that impression goes beyond the clinical evidence.

Cell-based products differ in their source, processing, composition, regulatory status and proposed mechanism. Studies of bone-marrow-derived preparations, adipose-derived cells and other products cannot automatically be treated as evidence for one another.

Even when a study reports improvements in pain or function, that does not necessarily demonstrate that new, durable articular cartilage has formed. Symptom improvement and structural regeneration must be measured separately.

The ACR's 2026 guidance strongly recommends against stem-cell injections for knee and hip osteoarthritis, with moderate certainty of evidence.

In the United States, the FDA states that regenerative medicine products have not been approved for orthopedic conditions such as osteoarthritis or knee pain. This is a US regulatory statement; patients elsewhere should verify local approval and registration requirements.

Risks can include infection and complications related to the product or procedure. More broadly, regulatory warnings about inadequately studied regenerative products should not be dismissed merely because a clinic describes a treatment as natural or derived from the patient's own cells.

Practical advice: Outside a properly regulated clinical trial, be skeptical of claims that stem-cell injections will regrow cartilage, reverse end-stage osteoarthritis or reliably prevent knee replacement.

Sources: ACR 2026 guidance and the FDA consumer alert on regenerative medicine products.

7. GLP-1 vs Knee Replacement: Can Weight Loss Avoid Surgery?

Weight loss and symptom improvement may help some patients defer surgery, but it is not yet possible to identify reliably who will avoid knee replacement because of GLP-1 treatment.

A retrospective database study published in 2026 found that GLP-1 receptor agonist use was associated with a lower long-term incidence of total knee arthroplasty among people with knee osteoarthritis. In one analysis, three years of semaglutide or tirzepatide exposure was associated with an absolute difference of 4.71 percentage points in estimated arthroplasty incidence at eight years compared with a matched unexposed group.

This finding is promising but should be interpreted cautiously. The study was observational, not a randomized trial designed to test whether GLP-1 medicines prevent knee replacement. Differences between treated and untreated patients can remain even after statistical matching.

The association does not prove that the medicines caused the reduction, that they regenerate cartilage or that patients can safely postpone surgery when symptoms are severe.

Source: 2026 retrospective database analysis of GLP-1 receptor agonists and knee arthroplasty.

When should someone consider knee replacement?

Joint replacement may be appropriate when pain, stiffness, impaired mobility or progressive deformity substantially affects daily life and nonsurgical management has been ineffective or unsuitable.

Options such as exercise, weight management, pain medication and rehabilitation should be considered according to the patient's needs and medical circumstances. However, there is no universal requirement to try every available injection before seeking an orthopedic opinion.

The UK's National Institute for Health and Care Excellence (NICE) advises clinicians to consider referral for joint replacement when symptoms substantially affect quality of life and nonsurgical management is ineffective or unsuitable. Its guidance also states that people should not be excluded from referral solely because they have overweight or obesity.

Source: NICE guideline: Osteoarthritis in over 16s — recommendations.

8. What Should Patients Do Alongside GLP-1 Treatment?

Weight loss alone is not a complete knee osteoarthritis treatment plan. A useful approach combines weight management, appropriate physical activity, strength preservation and symptom control.

Prioritize muscle strength

The quadriceps, hamstrings, hip muscles and other supporting muscles contribute to movement and joint stability. A personalized strength-training and rehabilitation plan may improve function, even when complete pain relief is not possible.

Patients losing weight rapidly should pay attention to muscle strength, adequate nutrition and physical function. Resistance exercise and sufficient dietary protein may help support muscle preservation, although individual requirements vary with age, kidney function, overall health and nutritional status.

A physiotherapist can adapt exercise to pain severity, balance, mobility and current fitness. Walking, stationary cycling, water-based exercise and progressive resistance training may be appropriate depending on symptoms and individual circumstances.

Use appropriate symptom management

Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are an established option for many people with knee osteoarthritis. Oral NSAIDs may help some patients, but gastrointestinal, kidney and cardiovascular risks must be considered.

Intra-articular corticosteroid injections may provide short-term symptom relief for selected patients. They should not be presented as cartilage-regenerating treatment.

Other interventions, including braces, walking aids and supervised rehabilitation, may be useful depending on which structures are affected and how much walking or standing is limited.

Monitor function, not just the number on the scale

A treatment plan should track outcomes that matter to the patient. These may include:

Pain during walking, standing and climbing stairs.
Ability to get up from a chair and complete daily activities.
Walking distance, sleep quality and participation in exercise.
Body weight, muscle strength, adverse effects and nutritional adequacy.

Improvements in weight do not guarantee parallel improvements in knee function. Conversely, a patient may benefit from improved strength and mobility even if weight loss is modest.

9. GLP-1 Safety and Practical Considerations

GLP-1 receptor agonists are prescription medicines used for specific metabolic and weight-management indications. They are not interchangeable with supplements or unregulated weight-loss products.

Semaglutide commonly causes gastrointestinal adverse effects such as nausea, vomiting, diarrhea and constipation. Gallbladder problems and other significant adverse effects may occur. Product-specific contraindications and precautions must be reviewed with the prescribing clinician.

Before treatment, discuss other medications, diabetes management, previous gastrointestinal or gallbladder problems, pregnancy plans where relevant, and the possibility of inadequate nutrition during substantial weight loss.

The semaglutide dose studied in STEP 9 was 2.4 mg weekly. This does not mean that every person with knee osteoarthritis should receive that dose or that a patient should change an existing prescription based on this article.

Does GLP-1 treatment need to continue indefinitely?

Obesity is often a chronic condition, and weight regain can occur after stopping effective weight-management medication. A treatment plan should therefore address maintenance, physical activity, nutrition, affordability and the risks and benefits of ongoing therapy.

For knee osteoarthritis, the ideal duration of GLP-1 treatment, the best strategy after discontinuation and the long-term effect on joint structure remain areas for further research.

10. A Practical Decision Guide

Clinical situation	Reasonable next step	Important limitation
Knee osteoarthritis with obesity and a need for weight management	Discuss appropriate weight-management options, including GLP-1 treatment, alongside diet, exercise and rehabilitation.	Pain relief is not guaranteed, and treatment must be medically appropriate.
Knee pain with a healthy body weight	Assess the diagnosis, joint damage, muscle strength and established treatment options.	Current evidence does not justify starting GLP-1 medication solely as a knee pain treatment in someone without an appropriate weight-management indication.
Persistent symptoms despite exercise and medication	Arrange reassessment and discuss additional treatment options, including orthopedic evaluation.	PRP and stem-cell injections have important evidence limitations; neither is proven to regenerate cartilage reliably.
Advanced osteoarthritis with major disability	Seek an orthopedic assessment to discuss the benefits and risks of knee replacement.	Weight management may help overall health, but should not automatically delay an appropriate surgical assessment.

11. Frequently Asked Questions

Can Ozempic or Wegovy help knee osteoarthritis?

Semaglutide improved knee pain, physical function and body weight in the STEP 9 trial involving adults with obesity and symptomatic knee osteoarthritis. Wegovy is a semaglutide brand used for chronic weight management in eligible patients in the United States. Ozempic and Wegovy have different approved indications and dosing instructions. Neither should be considered an established cartilage-regenerating treatment.

Does semaglutide rebuild knee cartilage?

There is no established clinical evidence that semaglutide regenerates damaged knee cartilage in humans. The STEP 9 trial demonstrated improvements in symptoms and weight, not proven cartilage regrowth.

Is tirzepatide as effective as semaglutide for knee pain?

There is no direct head-to-head randomized trial establishing that tirzepatide provides the same degree of knee pain relief as semaglutide in osteoarthritis. Tirzepatide has evidence for weight management in eligible patients and was included in observational research on arthroplasty outcomes, but those findings do not establish equivalent pain relief.

Is GLP-1 better than PRP for knee osteoarthritis?

There is no direct randomized comparison establishing that GLP-1 medication is superior to PRP for knee pain. The treatments have different targets: GLP-1 medication can help eligible patients manage obesity, while PRP is injected into the joint. The 2026 ACR guidance conditionally recommends GLP-1 receptor agonists for weight management in people with knee osteoarthritis and obesity, but strongly recommends against routine PRP treatment.

Are stem-cell injections better than GLP-1 medication?

No reliable direct comparison establishes that stem-cell injections are better than GLP-1 medication for knee osteoarthritis. Claims that stem-cell injections reliably regenerate cartilage or prevent knee replacement go beyond the available evidence. The 2026 ACR guidance strongly recommends against stem-cell injections for routine knee and hip osteoarthritis treatment.

Can I avoid knee replacement if I lose enough weight?

Some people may experience enough improvement to postpone surgery, but others continue to have substantial pain and disability even after weight loss. No particular amount of weight loss guarantees that knee replacement can be avoided. Decisions should be based on symptoms, function, clinical assessment and patient preferences.

Should I lose weight before seeing a knee surgeon?

Weight management may improve health and help optimize surgical preparation, but an orthopedic assessment should not automatically be postponed until a target weight is reached. Referral decisions should take account of symptom burden, the expected benefits and risks of surgery, and individual medical circumstances.

Does the 2026 ACR guideline recommend GLP-1 medications for everyone with knee osteoarthritis?

No. It conditionally recommends GLP-1 receptor agonists for people with knee osteoarthritis and obesity to help achieve an appropriate weight alongside diet and exercise. This is not a blanket recommendation for people of healthy weight or a declaration that GLP-1 medicines directly treat cartilage damage.

What is the best first-line treatment for knee osteoarthritis?

Exercise, appropriate weight management for people with overweight or obesity, education and self-management are foundational treatments. Topical NSAIDs are an established medication option for many patients. The best combination depends on symptoms, medical history, disease severity and individual goals.

12. References and Further Reading

Bliddal H, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine. 2024;391:1573–1583. DOI: 10.1056/NEJMoa2403664.
Gudbergsen H, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. American Journal of Clinical Nutrition. 2021;113:314–323. DOI: 10.1093/ajcn/nqaa328.
American College of Rheumatology. 2026 Osteoarthritis Guideline. Recommendations approved September 8, 2026. Guideline and summary.
GLP-1 receptor agonists and weight-loss strategies for individuals with obesity and hip or knee osteoarthritis: a scoping review. British Journal of Sports Medicine. 2026. Read the review.
Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis. Regional Anesthesia & Pain Medicine. 2026. Read the study.
American Academy of Orthopaedic Surgeons. Management of Osteoarthritis of the Knee (Non-Arthroplasty): Evidence-Based Clinical Practice Guideline. Read the guideline.
National Institute for Health and Care Excellence. Osteoarthritis in over 16s: diagnosis and management. Read the recommendations.
U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Read the safety alert.

Conclusion: Treat the Whole Patient, Not Just the Knee

GLP-1 therapy represents a meaningful development for people living with both obesity and knee osteoarthritis. The semaglutide STEP 9 trial demonstrated substantial improvements in weight, pain and physical function, and the 2026 ACR guidance now recognizes GLP-1 receptor agonists as a conditional option for appropriate weight management in this population.

But symptom relief is not proof of cartilage regeneration. The potential for GLP-1 medicines to directly alter osteoarthritis progression remains an important research question. PRP and stem-cell injections have their own limitations, and regenerative claims should be evaluated against clinical outcomes rather than marketing language.

For many patients, the most defensible strategy is a combination of appropriate weight management, progressive exercise, muscle preservation, symptom control and timely orthopedic assessment when needed. The goal is not simply to postpone surgery or achieve a lower number on the scale. It is to improve mobility, reduce suffering and preserve quality of life.

Medical disclaimer: This article is for educational purposes and does not replace individualized medical advice, diagnosis or treatment. Decisions about prescription medicines, injections and surgery should be made with appropriately qualified healthcare professionals. Do not start, stop or change medication based solely on this article.